Evidence map›Paper›PMID 36389677›Full record

ArticleFrontiers in immunology2022

A novel asexual blood-stage malaria vaccine candidate: PfRipr5 formulated with human-use adjuvants induces potent growth inhibitory antibodies.

Eizo Takashima, Hikaru Nagaoka, Ricardo Correia, Paula M Alves, António Roldão, Dennis Christensen, Jeffrey A Guderian, Akihisa Fukushima, Nicola K Viebig, Hilde Depraetere and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eizo TakashimaDivision of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama, Japan.
Hikaru NagaokaDivision of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama, Japan.
Ricardo CorreiaiBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Paula M AlvesiBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
António RoldãoiBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Dennis ChristensenCenter for Vaccine Research, Statens Serum Institut (SSI), Copenhagen, Denmark.
Jeffrey A GuderianAccess to Advanced Health Institute, Seattle, WA, United States.
Akihisa FukushimaVaccines, Sumitomo Pharma Co., Ltd., Osaka, Japan.
Nicola K ViebigEuropean Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.
Hilde DepraetereEuropean Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.
Takafumi TsuboiDivision of Cell-Free Sciences, Proteo-Science Center, Ehime University, Matsuyama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PfRipr is a highly conserved asexual-blood stage malaria vaccine candidate against

Indexed as

Malaria VaccinesAdjuvants, ImmunologicAdjuvants, PharmaceuticAnimalsAntibodies, ProtozoanAntigens, ProtozoanHumansPlasmodium falciparumRabbitsAdjuvants, ImmunologicAdjuvants, PharmaceuticAntibodies, ProtozoanAntigens, ProtozoanMalaria VaccinesadjuvantAlhydrogelasexual blood-stage malaria vaccineCAF01GLA-SEPfRipr5Plasmodium falciparum

Identifiers

PMID36389677
PMCPMC9647036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.